Advanced Search

Study Preview



Study Title and Description

Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection.



Key Questions Addressed
8 Key Question 8 - Case studies/series and potential harms of nonstandard interventions for CDI
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection.
Author Herpers BL., Vlaminckx B., Burkhardt O., Blom H., Biemond-Moeniralam HS., Hornef M., Welte T., Kuijper EJ.
Country Department of Medical Microbiology and Immunology, St. Antonius Hospital, PO Box 2500, Nieuwegein 3430 EM, The Netherlands. b.herpers@antonius.net
Year 2009
Numbers Pubmed ID: 19435431
1441 (internal)

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Key Question 4 - Case studies/series and potential harms of nonstandard interventions for CDI (Table C11)
Design Details
Question... Follow Up Answer Follow-up Answer
Study Focus Treatment for severe refractory C. difficile infection
  • Comments Comments (
    0
    ) |
Subject/Study Details 4 patients with diarrhea, positive C. difficile toxin stool and pseudomembranes as well as septic or hypovolemic shock and other serious health problems 2 males, 59 and 36 years old and 2 females, 36 and 82 years old
  • Comments Comments (
    0
    ) |
Interventions Intravenous tigecycline 100 mg x 1 dose then 50 mg twice/day for 7- 24 days 3 patients were treated with standard antibiotics along with tigecycline
  • Comments Comments (
    0
    ) |
Clinical Diarrhea Outcomes
  • Comments Comments (
    0
    ) |
C. difficile Toxin, C. difficile Culture, or Other Clinical signs (e.g., diarrhea) improved within 7 d C. difficile toxin became negative in 3 patients within 7 d and after continued oral vancomycin in 1 patient in 2 weeks No recurrence was reported in 3 weeks
  • Comments Comments (
    0
    ) |
Adverse Effects (AE) Harms
  • Comments Comments (
    0
    ) |




Results & Comparisons

No Results found.